CF Industries Holdings CF
Basic Materials · Agricultural Inputs · Synthos Deep Dive · 2026-07-03
The Overview
CF Industries makes nitrogen fertilizer — ammonia, urea, and UAN — the stuff farmers spread to grow corn and wheat. It also sells nitrogen for industrial uses and is building a "low-carbon" (blue) ammonia plant. It's a commodity business: when natural gas is cheap (their main raw material) and fertilizer prices are high, they mint cash; when that flips, profits shrink.
Right now the stock looks cheap — you're paying about $10 for every $1 of last year's profit, and the company is loaded with cash and buying back tons of its own shares. The catch is that this year's profits are unusually high and Wall Street's own analysts expect earnings to fall over the next several years as fertilizer prices cool off. So "cheap" can be a trap if you buy at the top of the cycle.
Our verdict is Watch — a fine, sturdy company, but not a bargain at today's price and not a grower. Wait for a cheaper entry or a clear turn in the fertilizer cycle.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The balance sheet is rock-solid and the stock is not jumpy — but earnings ride a boom-and-bust commodity cycle, and we're near a boom.
- Growth Quality 4/10 (below average). The company is very profitable today, but that's the cycle, not durable growth; analysts see earnings shrinking.
- Exponential Potential 2/10 (low). This is a mature producer in a flat market. Don't expect it to multiply.
The one big worry: the fertilizer/natural-gas price cycle turns down and earnings roughly halve from the 2026 peak — which is exactly what the estimates already pencil in.
Putting a number on it: our fair-value estimate is $115 against a current price of $125.77 — a premium price for a business we still like.
Our summary metrics
Fortress balance sheet (net-debt/EBITDA 0.43×) & low 0.38 beta offset by deep commodity cyclicality and a peak-earnings 2026.
No secular growth — forward EPS estimates DECLINE from a 2026 nitrogen-price peak; high ROE is cycle-inflated, not durable.
A mature, cyclical commodity producer; TAM is flat global nitrogen demand and growth is decelerating — the opposite of exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature, cyclical commodity producer; TAM is flat global nitrogen demand and growth is decelerating — the opposite of exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $112.5 (high $145 / low $72; 21 Buy · 14 Hold · 6 Sell) — context, not our anchor |
| Valuation | 9.9× trailing EPS · ~6.4× FY26E · 9.6× FY27E · 15× FY30E · EV/S 2.5× · EV/EBITDA 5.0× · FCF yield ~9.5% |
| Technicals | Mixed — $110.54, −19.7% off 52-wk high, above 200-DMA ($100) but below 50-DMA ($116), RSI 59, −13.6% 3-mo |
| Conviction | Low — 0 expert voices in the Synthos KB; call rests entirely on fundamentals + quant |
| Position sizing | Satellite / tactical only, ≤2% if owned at all — a cyclical value name, not a compounder |
What the experts actually said 5 traceable claims on CF · showing the highest-conviction voices
“Ammonia is still 5x its 2019-2020 average; with US gas in the low sixes vs Dutch TTF at 40, that spread is the bread-and-butter of CF Industries' profitability and UK fertilizer shutdowns only tighten it further.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $125.79, 7% above the 50-day average ($118), 18% above the 200-day average ($107) — an uptrend. 9% below the 52-week high of $138, 65% above the 52-week low of $76.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $125.79 is currently inside the band (band $112–$130).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 57.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.47, positive momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = CF · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
CF Industries Holdings (NYSE: CF) is a global producer and distributor of hydrogen- and nitrogen-based products — anhydrous ammonia, granular urea, urea ammonium nitrate (UAN), and ammonium nitrate (AN), plus industrial nitrogen products (diesel exhaust fluid, nitric acid, urea liquor). Founded 1946, headquartered in Northbrook/Deerfield, Illinois, ~2,800 employees. Its structural edge is access to low-cost North American natural gas (the primary feedstock for ammonia), which makes it one of the lowest-cost nitrogen producers globally. Fiscal year ends December 31.
The forward strategic bet is the Blue Point Complex — a low-carbon (autothermal-reforming) ammonia facility with carbon capture and sequestration, built with joint-venture partners, aimed at the emerging clean-ammonia/hydrogen-economy market. This is capital-heavy and multi-year; management flags it repeatedly as both the growth avenue and the main execution risk (see §9).
Revenue mix (FY2025, from filings):
- By product: Ammonia $2.18B (31%) · UAN $2.16B (31%) · Urea $1.78B (25%) · AN $0.42B (6%). A concentrated, single-nutrient (nitrogen) commodity mix — no diversification cushion when nitrogen spreads compress.
- By geography: United States $5.34B (~75%) · Canada $0.60B · UK $0.38B · rest-of-world ~$0.77B. Heavily North-America-weighted production and demand.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of CF in the Synthos knowledge base. total_claims = 0; zero net-bullish voices; zero cautionary voices. We therefore cite no claim_ids — to do so would be fabrication, which the house standard forbids.
That absence is itself information: CF is a cyclical basic-materials commodity name, not the kind of secular-growth or platform story the Synthos expert panel tends to cover. This verdict is 100% fundamentals- and quant-driven — built from FMP financials, analyst estimates, and valuation/quality/cyclicality signals, with no borrowed conviction. Read the scores and cases below as a pure numbers-and-cycle read, and weight them accordingly.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Balance sheet is a fortress — net-debt/EBITDA 0.43×, current ratio 3.5×, beta 0.38, interest coverage 17× — and the stock is cheap (10× P/E). But earnings are cyclical and near a 2026 peak, the business is single-commodity (nitrogen), and gas-price/weather swings drive results. Cheapness partially offsets cyclicality; net moderate. |
| Growth Quality | 4 · Below Average | ROE 35% and ROIC 15% look elite, but they are cycle-inflated, not durable — the same metrics were far lower in the 2020 trough. Forward EPS estimates decline ($17 FY26E → ~$7 FY30E). Margins are high now but mean-revert with nitrogen prices. High returns, low durability. |
| Exponential Potential | 2 · Low | A mature producer in a flat global-nitrogen TAM; the 2nd derivative of growth is negative on consensus. Blue Point clean-ammonia optionality exists but is years out and capital-heavy. Nothing here accelerates. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Because CF is cyclical, the right anchor is mid-cycle earnings power at a mid-cycle multiple, not the 2026 peak.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Nitrogen spreads stay elevated (tight global supply, cheap US gas); Blue Point de-risks. ~$12.50 mid-cycle EPS at a ~12× cyclical-peak multiple; buybacks shrink the count. | ~$150 (+36%) |
| Base (our anchor) | Cycle normalizes toward a ~$11.5 FY27E EPS at a ~10× through-cycle multiple; continued ~$1.4–1.8B/yr buybacks provide a per-share tailwind. | ~$115 (+4%) |
| Bear | Gas/ammonia spreads compress; EPS reverts toward the ~$7–8 2029–30E range at a ~9–10× trough multiple as the market prices the down-leg. | ~$78 (−29%) |
Synthos fair value = the base case, ~$115 (+4%), with the full $78–$150 span as the honest range. Note how tight the base is to today's $110.54 and to the Street's $112.5 consensus — there is no obvious edge at this price. The asymmetry (−29% bear vs +36% bull) is roughly two-sided, which is exactly why this is a Watch, not a Buy: you want to own cyclicals when they're hated and cheap on trough earnings, not at Street fair value on peak earnings. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers). CF is neither — it is a cyclical commodity producer, and it scores 2/10 here honestly:
- Forward growth is negative, not exponential. Consensus EPS: FY26E $17.18 → FY27E $11.55 → FY28E $9.19 → FY29E $7.03 → FY30E $7.36. Revenue similarly drifts from ~$8.6B FY26E toward ~$6.4B FY30E. The 2026 figure is a spike (elevated nitrogen prices / gas spreads), and every later year is a step down. The second derivative is firmly negative.
- Room to run is capped by a flat TAM. Global nitrogen-fertilizer demand grows low-single-digits with population and acreage — there is no expanding addressable market to compound into. CF's growth comes from volume debottlenecking and price cycles, not a widening market.
- The one real option is Blue Point clean ammonia — a genuine call on a future hydrogen/low-carbon-ammonia economy. But it is years from contributing, capital-intensive, and dependent on policy and offtake markets that don't yet exist at scale. It is optionality, not a base-case growth engine.
- Capital return, not reinvestment growth. CF shrinks its share count aggressively (weighted diluted shares fell from ~204M in 2022 to ~154M by Q1'26) — that is the per-share growth lever, and it is financial engineering on a flat-to-cyclical earnings base, not organic exponential growth.
Exponential Potential: Low. Own CF (if at all) for cheap cyclical cash flow and buybacks near a trough — never for growth compounding.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $7.08B, +19.3% off FY24's $5.94B — but recall FY22 was $11.19B at the last nitrogen peak, then $6.63B (FY23) → $5.94B (FY24). This is the signature of a commodity cycle, not a growth curve.
- Quarterly trajectory (the 2026 inflection): Q1'25 $1.66B → Q2 $1.89B → Q3 $1.66B → Q4 $1.87B → Q1'26 $1.99B (+19.4% YoY). Prices/spreads are re-inflating in early 2026 — which is what drives the elevated FY26E estimates.
- Margins: gross 40.4% TTM, EBITDA margin 50% TTM, net 23.7% TTM — very high, but these are peak-cycle margins. In the FY20 trough, gross margin was ~20% and net income was ~$317M vs $1.46B FY25.
- Earnings: FY25 net income to CF stockholders $1,455M, diluted EPS $8.97. Note the gap between net income from continuing operations ($1,798M) and bottom-line net income ($1,455M) — ~$343M accrues to noncontrolling interests (JV partners in CF's nitrogen complexes). TTM EPS ~$11.15 reflects the strong Q1'26 ($3.99).
- Cash flow: FY25 operating CF $2.75B, capex −$950M (rising with Blue Point), FCF $1.80B (~9.5% FCF yield). Capex is stepping up — FY24 capex was only $518M — so free cash flow will be pressured during the Blue Point build.
- Balance sheet: total debt $3.95B, cash $1.98B, net debt $1.97B, net-debt/EBITDA 0.43× — very conservative. Minority interest $2.94B is large (the JV structure). Investment-grade (letter rating A-).
- Capital return: FY25 buybacks −$1.38B and dividends −$326M (dividend $2.00/yr, ~1.8% yield, payout only ~18%). Return-of-capital is the core shareholder story.
6. Valuation — priced in or room?
On trailing numbers CF looks cheap: 9.9× EPS, 5.0× EV/EBITDA, 2.5× EV/sales, ~9.5% FCF yield, 3.2× book. But cyclical cheapness is a trap when earnings are peaking. The forward P/E path — ~6.4× FY26E (peak) → 9.6× FY27E → ~13× FY28E → ~15× FY30E — rises as EPS falls, the classic "cheap on peak, expensive on trough" signature of a commodity name. The honest way to value CF is mid-cycle EPS (~$11–12) × a through-cycle multiple (~9–10×) ≈ $105–120, which is right where the stock trades. Street targets (context): consensus $112.5, median $114, high $145, low $72 — a wide spread that reflects genuine disagreement about where the cycle goes. Our ~$115 base sits essentially on top of consensus and spot. Conclusion: fairly valued, not cheap once you normalize for the cycle. No margin of safety at $110.
7. Technicals (from the tech block)
- Trend: mixed/consolidating. $110.54 sits above the 200-DMA ($99.85) but below the 50-DMA ($116.00) — a short-term downtrend inside a longer-term uptrend. MACD −2.4 (negative). No clean golden/death-cross signal.
- Location: −19.7% off the 52-week high ($137.60), +45% off the 52-week low ($76.09) — mid-range, with a meaningful ~20% drawdown from the peak (unlike a leadership name pinned to highs).
- Momentum: RSI(14) 59 — neutral, neither overbought nor oversold. No stretched-entry signal either way.
- Relative strength: +19.5% 12-mo vs SPY +20.6% and QQQ +30.3% — CF has lagged both the market and the Nasdaq over 12 months, and is −13.6% over 3 months while SPY was +13.7%. Recent underperformance.
- Read: technicals are neutral-to-soft — a stock digesting a pullback, holding its 200-DMA but capped below the 50-DMA. Nothing here argues for urgency; a base near/below the 200-DMA would be a more favorable cyclical entry.
8. Moat & competitive position
CF's moat is cost-based, not franchise-based: privileged access to low-cost North American natural gas plus large-scale, well-run ammonia complexes make it a low-cost producer in a global commodity. That is a real and durable edge on the cost curve — but it does not confer pricing power. Nitrogen products are fungible global commodities; CF is a price-taker whose margins are set by the gas-to-ammonia spread and global supply/demand, not by brand or switching costs. The Blue Point low-carbon ammonia project is an attempt to build a differentiated (green-premium) product, but that market is nascent.
Peer set (FMP-supplied, market cap): these are a grab-bag of basic-materials names — Mosaic (MOS, $6.7B, the closest fertilizer comp), ICL Group ($6.5B), SQM ($20.8B, lithium/specialty), LyondellBasell ($17.2B, petrochem), Reliance Steel ($19.0B), CEMEX ($17.8B), RPM ($14.2B), Suzano ($9.7B, pulp), plus gold/silver miners (AGI, PAAS). The only true nitrogen/fertilizer peer here is Mosaic; the rest are unrelated cyclicals. Against fertilizer peers CF is the higher-quality, lower-cost, better-balance-sheet operator — but all share the same commodity-cyclicality problem.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — ~$1.38B buybacks + $326M dividends in FY25 against $1.8B FCF, funded from a 0.43× net-debt/EBITDA balance sheet. The aggressive buyback (share count down ~25% since 2022) is the primary per-share value lever and is appropriate given a mature, cash-generative, low-growth base. Blue Point is the main organic reinvestment.
- Insider activity: the recent Form 4s in the window are routine equity awards (director/officer grants at $0 cost — e.g. new CFO Andrew Scribner's award, director annual grants) — not open-market purchases or a cluster of discretionary selling. Neutral signal.
- Management's own guidance (the earnings-release track): the SEC 8-K (Item 2.02) Q1'26 earnings materials were retrieved, but the extracted text is the safe-harbor / non-GAAP-definitions boilerplate, not hard forward guidance. Consistent with CF's practice as a commodity producer, management does not issue point revenue or EPS guidance — it guides on capex, volumes, and the Blue Point project timeline rather than earnings. Their forward commentary (management's own, self-interested words — half-weighted) centers on: executing the Blue Point low-carbon ammonia JV on schedule and budget, the growth of a low-carbon ammonia/hydrogen market, projected capital expenditures, and GHG-reduction targets. No quantitative earnings guidance was available in the retrieved release; we do not fabricate any. Treat the estimates in this note as analyst consensus (FMP), not company guidance.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q2'26; Street EPS $5.71, revenue ~$2.47B). The key lines: realized nitrogen prices, the natural-gas cost spread, and Blue Point capex/timeline.
- Nitrogen price cycle: ammonia/urea/UAN benchmark prices and global supply (Chinese export policy, European gas-driven curtailments) — the dominant earnings driver.
- Natural-gas cost: CF's feedstock; cheap, stable US gas is the whole cost-advantage thesis.
- Blue Point Complex: construction on-schedule/on-budget milestones and offtake/partner commitments — the multi-year growth-and-risk swing factor.
- Capital return: pace of buybacks and any dividend increase — the per-share tailwind.
Thesis tripwires (what would change the call): a decisive break of the 200-DMA on falling nitrogen prices (buy-the-trough setup improving), a Blue Point cost overrun/delay (bear), or a sustained spread expansion that resets mid-cycle earnings power higher (bull).
11. Key risks
- Commodity cyclicality (structural, the #1 risk): earnings are driven by nitrogen prices and gas spreads and swing violently — FY22 EPS $16.46 vs FY20 EPS $1.48. Analysts already model EPS falling from the 2026 peak toward ~$7 by 2030. Buying near the top of the cycle is the core danger.
- Natural-gas price shock: a rise in North American gas erodes the cost advantage and margins directly.
- Single-commodity concentration: ~100% nitrogen; no product diversification to cushion a nitrogen down-cycle.
- Blue Point execution: a large, capital-intensive, first-of-kind low-carbon ammonia JV — cost overruns, schedule slips, or a slow-to-develop clean-ammonia market would impair returns.
- Policy / tariffs / trade: fertilizer demand and input costs are exposed to agricultural policy, tariffs, and global trade friction (management's own listed risk factors).
- Weather/seasonality: planting seasons and adverse weather swing quarterly demand.
- No expert corroboration: with zero KB coverage, this call has no independent-voice cross-check — it rests solely on the numbers and the cycle read.
12. Verdict, position sizing & monitoring
Watch. CF is a genuinely well-run, low-cost, cash-generative nitrogen producer with a fortress balance sheet (0.43× net-debt/EBITDA), a low 0.38 beta, a ~9.5% FCF yield, and an aggressive buyback — a lot to like on quality and financial strength. But two things hold it back from a Buy: (1) it is not cheap once you normalize the cycle — at $110 it trades right on Street consensus ($112.5) and our own mid-cycle fair value (~$115), on peak 2026 earnings; and (2) there is no growth — the analysts' own estimates show EPS declining from the 2026 spike toward ~$7 by 2030, and the business sits in a flat-TAM commodity market. The right way to make money in CF is to buy it hated and cheap on trough earnings; today it is neither.
- Sizing: if owned at all, satellite/tactical, ≤2% — a cyclical value/return-of-capital position, never a core compounder. Prefer to wait for a cycle-driven pullback (toward/below the 200-DMA on falling nitrogen prices) for a better risk/reward entry.
- Monitoring: re-underwrite on the §10 tripwires; re-score each earnings print with special attention to realized nitrogen prices, the gas spread, and Blue Point milestones. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $110.54.
- Single biggest risk: nitrogen-price cyclicality — the down-leg of the commodity cycle, which the consensus estimates already anticipate.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of CF in the Synthos knowledge base, so no
claim_ids are cited. The verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none was borrowed here. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates — CF does not issue point EPS/revenue guidance.
- Management caveat: management's forward commentary (Blue Point, capex, clean-ammonia market) is its own self-interested book, half-weighted by design; no quantitative guidance was available in the retrieved 8-K.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").